Furthermore, in a mouse model of Alzheimer’s disorder (AD), slow-release of IGF-1 systemically enhanced cognitive performance, decreased amyloid levels and protected synapses (Butovsky et al., 2006). This evidence concerns the gene IGF1 and Alzheimer disease.